GlassScriptPhysician profile
Brian C Hayes
NPI 1699767038
$4,069.96
in general payments reported to CMS, 2019-2025
21 companies · $678 in 2025
The $678 reported for 2025 was more than what 84% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $979 · 2020: $377 · 2021: $484 · 2022: $749 · 2023: $365 · 2024: $438 · 2025: $678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,353 · Entertainment: $128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,352.68 |
| Entertainment | $128.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $672.88 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $670.57 | 2022-2025 | Miebo, Infuse, Xiidra |
| Coopervision INC. | $451.31 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Allergan, INC. | $435.75 | 2019-2022 | |
| Alcon Vision LLC | $342.32 | 2019-2023 | Total30 |
| Johnson & Johnson Vision Care, INC. | $234.36 | 2019-2025 | Acuvue |
| Optos, INC. | $219.20 | 2021-2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Tarsus Pharmaceuticals, INC. | $210.73 | 2025 | Xdemvy |
| Oyster Point Pharma, INC. | $138.59 | 2022-2025 | Tyrvaya |
| Harrow Eye, LLC | $124.79 | 2024-2025 | Vevye |
| Lombart Brothers, INC. | $119.83 | 2022 | |
| Sun Pharmaceutical Industries INC. | $91.87 | 2019-2022 | |
| Sight Sciences, INC. | $87.94 | 2022-2024 | Tearcare System |
| Glaukos Corporation | $70.34 | 2019 | |
| Novartis Pharmaceuticals Corporation | $58.52 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $56.59 | 2025 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Dompe US, INC. | $18.21 | 2024 | Oxervate |
| Tearlab Corp | $17.63 | 2021 | |
| Lkc Technologies, INC. | $14.64 | 2024 | |
| Horizon Therapeutics Plc | $14.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Hayes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.